Growth Hormone Peptides: A Research Guide to GHRPs, GHRHs, and Secretagogues
Research Use Only. This article is for scientific and educational reference only. All products are sold for research purposes and are not intended for human or animal consumption.
Introduction
Growth hormone (GH) secretion is regulated by a complex interplay of stimulatory and inhibitory signals from the hypothalamus, pituitary, and peripheral tissues. Research into compounds that modulate this axis -- collectively termed growth hormone secretagogues -- has produced a diverse class of peptides and small molecules with distinct mechanisms, pharmacokinetic profiles, and research applications.
This guide covers the major categories of GH-axis research compounds: growth hormone-releasing peptides (GHRPs), growth hormone-releasing hormone analogs (GHRHs), and second-generation secretagogues, with a focus on the preclinical and clinical evidence base for each.
The Growth Hormone Axis: A Brief Overview
Growth hormone is synthesized and secreted by somatotroph cells in the anterior pituitary gland. Its release is primarily regulated by two hypothalamic hormones:
- Growth hormone-releasing hormone (GHRH): Stimulates GH synthesis and secretion through the GHRH receptor (GHRHR) on somatotrophs - Somatostatin (SST): Inhibits GH secretion, acting as the primary brake on the axis
A third regulatory pathway was discovered in the 1970s when researchers found that certain synthetic enkephalin analogs could stimulate GH release through a mechanism distinct from GHRH. This led to the identification of the ghrelin receptor (GHS-R1a) and the growth hormone secretagogue (GHS) class of compounds.
GH itself acts primarily through the GH receptor to stimulate production of insulin-like growth factor 1 (IGF-1) in the liver, which mediates many of GH's anabolic and metabolic effects.
Growth Hormone-Releasing Peptides (GHRPs)
GHRPs are synthetic peptides that stimulate GH release by activating the ghrelin receptor (GHS-R1a). The first-generation GHRPs were developed in the 1980s and 1990s.
GHRP-6
GHRP-6 (His-D-Trp-Ala-Trp-D-Phe-Lys-NH2) was among the first synthetic GHS compounds studied. It produces robust GH pulses but is associated with significant increases in appetite and cortisol, limiting its research utility in some contexts. It also stimulates prolactin release.
GHRP-2
GHRP-2 produces stronger GH stimulation than GHRP-6 with somewhat less appetite stimulation, but retains the cortisol and prolactin effects. It has been used in clinical research as a diagnostic tool for GH deficiency assessment.
Ipamorelin
Ipamorelin represents a significant advance in GHRP design. It produces selective GH stimulation with minimal effects on cortisol, prolactin, or appetite -- a profile that has made it one of the most widely studied GHRPs in both preclinical and clinical settings.
Key characteristics of ipamorelin: - High selectivity for GHS-R1a - Minimal cortisol and prolactin stimulation - No significant appetite stimulation at research doses - Half-life of approximately 2 hours - Suitable for repeated dosing protocols in research models
Clinical studies have demonstrated ipamorelin's ability to stimulate GH pulses comparable to GHRH, with a favorable safety profile in Phase 2 trials for postoperative ileus and other applications.
Hexarelin
Hexarelin is a more potent GHRP than ipamorelin but with less selectivity -- it stimulates cortisol and prolactin release and has demonstrated cardiac effects (both protective and potentially problematic at high doses) through mechanisms that may be partially independent of GH release.
Growth Hormone-Releasing Hormone Analogs (GHRHs)
GHRH analogs work through a distinct mechanism from GHRPs, activating the GHRHR on pituitary somatotrophs rather than the ghrelin receptor.
Sermorelin
Sermorelin (GHRH 1-29 NH2) is a truncated analog of native GHRH containing the first 29 amino acids, which retain full biological activity. It has been FDA-approved for diagnostic use in GH deficiency assessment and has been studied in clinical trials for GH deficiency treatment.
Sermorelin stimulates physiological GH release -- pulsatile, regulated by somatostatin feedback -- rather than the supraphysiological spikes associated with exogenous GH administration. This physiological profile has generated research interest in aging-related GH decline.
CJC-1295
CJC-1295 is a modified GHRH analog with two key innovations: substitution of four amino acids to increase DPP-4 resistance, and conjugation to a drug affinity complex (DAC) that enables covalent binding to albumin. This combination extends the half-life from minutes (native GHRH) to approximately 6-8 days, enabling once-weekly dosing.
Clinical studies have demonstrated that CJC-1295 with DAC produces sustained elevation of GH and IGF-1 levels over multiple days following a single injection, a profile distinct from the pulsatile stimulation produced by shorter-acting GHRH analogs.
Tesamorelin
Tesamorelin is a stabilized GHRH analog approved by the FDA for HIV-associated lipodystrophy. Clinical trials have demonstrated its ability to reduce visceral adipose tissue and improve lipid profiles in this population. It represents the most clinically advanced GHRH analog and provides important proof-of-concept data for the class.
Second-Generation Secretagogues: MK-677 (Ibutamoren)
MK-677 (ibutamoren) is a non-peptide, orally active GHS-R1a agonist -- the first compound in its class to demonstrate oral bioavailability. Unlike peptide GHRPs that require injection, MK-677 can be administered orally, which has significant implications for research protocols.
Clinical studies have demonstrated: - Sustained increases in GH and IGF-1 levels with once-daily oral dosing - Increased lean body mass and reduced fat mass in elderly subjects - Improved sleep quality (particularly slow-wave sleep, which is associated with GH secretion) - Increased appetite (a class effect of GHS-R1a agonism)
A Phase 2 clinical trial in elderly patients with hip fracture (MK-677-012) demonstrated improvements in functional outcomes and reduced hospitalization, providing clinical validation of GH secretagogue research in aging populations.
Combination Protocols in Research
A common research approach combines a GHRH analog (to prime the pituitary) with a GHRP (to amplify the GH pulse through the complementary ghrelin receptor pathway). This combination produces synergistic GH release greater than either compound alone.
| Combination | Mechanism | Research Application | |---|---|---| | CJC-1295 + Ipamorelin | GHRHR + GHS-R1a | Most studied combination; sustained GH elevation | | Sermorelin + GHRP-2 | GHRHR + GHS-R1a | Diagnostic and research use | | CJC-1295 + GHRP-6 | GHRHR + GHS-R1a | Stronger GH pulse; appetite stimulation noted | | Tesamorelin + Ipamorelin | GHRHR + GHS-R1a | Visceral fat reduction research |
The rationale for combination use is supported by clinical data showing that GHRH and ghrelin receptor pathways act synergistically at the pituitary level.
Research Applications
GH secretagogue research spans several therapeutic areas:
GH Deficiency: GHRH analogs and GHRPs have been studied as alternatives to exogenous GH replacement, with the advantage of stimulating physiological pulsatile GH release rather than continuous supraphysiological exposure.
Aging: Age-related decline in GH secretion (somatopause) has been a major research focus, with studies examining whether GH secretagogues can partially reverse the metabolic and body composition changes associated with aging.
Muscle Wasting: GH secretagogues have been studied in conditions associated with muscle wasting, including HIV wasting syndrome, cancer cachexia, and sarcopenia.
Wound Healing and Recovery: The anabolic effects of GH and IGF-1 have generated research interest in accelerating recovery from surgery, burns, and other tissue injuries.
References
- Bowers CY. "Growth hormone-releasing peptide (GHRP)." Cell and Molecular Life Sciences. 1998;54(12):1316-1329. https://pubmed.ncbi.nlm.nih.gov/9893710/
- Teichman SL, et al. "Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295." Journal of Clinical Endocrinology and Metabolism. 2006;91(3):799-805. https://pubmed.ncbi.nlm.nih.gov/16352683/
- Murphy MG, et al. "MK-0677, an orally active growth hormone secretagogue, reverses diet-induced catabolism." Journal of Clinical Endocrinology and Metabolism. 1998;83(2):320-325. https://pubmed.ncbi.nlm.nih.gov/9467536/
- Falutz J, et al. "Metabolic effects of a growth hormone-releasing factor in patients with HIV." New England Journal of Medicine. 2007;357(23):2359-2370. https://pubmed.ncbi.nlm.nih.gov/18057339/
- Nass R, et al. "Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults." Annals of Internal Medicine. 2008;149(9):601-611. https://pubmed.ncbi.nlm.nih.gov/18981487/
This article is intended for educational and laboratory reference purposes only. All research must comply with applicable institutional, local, and national regulations. This content does not constitute medical advice.